Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms

被引:8
|
作者
Teoh, Jeremy Yuen-Chun [1 ]
Tian, Xiao-Yu [2 ]
Wong, Christine Yim-Ping [1 ]
Lau, Chi-Wai [2 ]
Cheng, Chak-Kwong [2 ]
Tang, Victor Wai-Lun [3 ]
Chan, Ronald Cheong-Kin [4 ]
Huang, Yu [2 ]
Ng, Chi-Fai [1 ]
机构
[1] Chinese Univ Hong Kong, Dept Surg, SH Ho Urol Ctr, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Inst Vasc Med, Sch Biomed Sci, Fac Med, Hong Kong, Peoples R China
[3] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China
来源
PROSTATE | 2022年 / 82卷 / 01期
关键词
androgen deprivation therapy; cardiovascular risk; endothelial dysfunction; PROSTATE-CANCER; OXIDATIVE STRESS; HORMONE ANTAGONIST; TYROSINE NITRATION; RISK; TESTOSTERONE; PROSTACYCLIN; ORCHIECTOMY; ATHEROSCLEROSIS; INCREASES;
D O I
10.1002/pros.24244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Androgen deprivation therapy (ADT) is a key treatment modality in the management of prostate cancer (PCa), especially for patients with metastatic disease. Increasing evidences suggest that patients who received ADT have increased incidence of diabetes, myocardial infarction, stroke, and even mortality. It is important to understand the pathophysiological mechanisms on how ADT increases cardiovascular risk and induces cardiovascular events, which would provide important information for potential implementation of preventive measures. Methods Twenty-six 12-week-old male SD rats were divided into four groups for different types of ADTs including: the bilateral orchidectomy group (Orx), LHRH agonist group (leuprolide), LHRH antagonist group (degarelix), and control group. After treated with drug or adjuvant injection every 3 weeks for 24 weeks, all rats were sacrificed and total blood were collected. Aorta, renal arteries, and kidney were preserved for functional assay, immunohistochemistry, western blot, and quantitative reverse-transcription polymerase chain reaction. Results In vascular reactivity assays, aorta, intrarenal, and coronary arteries of all three ADT groups showed endothelial dysfunction. AT1R and related molecules at protein and messenger RNA (mRNA) level were tested, and AT1R pathway was shown to be activated and played a role in endothelial dysfunction. Both ACE and AT1R mRNA levels were doubled in the aorta in the leuprolide group while Orx and degarelix groups showed upregulation of AT1R in the kidney tissues. By immunohistochemistry, our result showed higher expression of AT1R in the intrarenal arteries of leuprolide and degarelix groups. The role of reactive oxygen species in endothelial dysfunction was confirmed by DHE fluorescence, nitrotyrosine overexpression, and upregulation of NOX2 in the different ADT treatment groups. Conclusion ADT causes endothelial dysfunction in male rats. GnRH receptor agonist compared to GnRH receptor antagonist, showed more impairment of endothelial function in the aorta and intrarenal arteries. Such change might be associated with upregulation and activation of AngII-AT1R-NOX2 induced oxidative stress in the vasculature. These results help to explain the different cardiovascular risks and outcomes related to different modalities of ADT treatment.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 50 条
  • [21] Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
    T Karantanos
    P G Corn
    T C Thompson
    Oncogene, 2013, 32 : 5501 - 5511
  • [22] Cardiovascullar risk with androgen deprivation therapy for prostate cancer: Potential mechanisms
    Tivesten, Asa
    Pinthus, Jehonathan H.
    Clarke, Noel
    Duivenvoorden, Wilhelmina
    Nilsson, Jan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (11) : 464 - 475
  • [23] OCCURRENCE CHARACTERISTIC OF METABOLIC COMPLICATIONS AFTER ANDROGEN DEPRIVATION THERAPY
    Tao, X.
    Jiaqi, X.
    Chunfang, Z.
    Xiaofeng, W.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 275 - 275
  • [24] Immunohistochemical changes in prostate cancer after androgen deprivation therapy
    Bostwick, DG
    MOLECULAR UROLOGY, 2000, 4 (03) : 101 - 106
  • [25] Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
    Ghadjar, Pirus
    Wiegel, Thomas
    LANCET ONCOLOGY, 2020, 21 (01): : E11 - E11
  • [26] Organic nitrates: Update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction
    Muenzel, Thomas
    Steven, Sebastian
    Daiber, Andreas
    VASCULAR PHARMACOLOGY, 2014, 63 (03) : 105 - 113
  • [27] Pattern of testosterone recovery after androgen deprivation therapy.
    Tam, Andrew
    Feng, Qianhua
    Shi, Juncong Ashley
    Ladbury, Colton John
    Correnti, Nicholas
    Zheng, Stephanie
    Wong, Jeffrey Y. C.
    Dandapani, Savita V.
    Glaser, Scott
    Rock, Adam
    Chehrazi-Raffle, Alexander
    Tripathi, Abhishek
    Pal, Sumanta Kumar
    Dorff, Tanya B.
    Li, Yun Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 330 - 330
  • [28] Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer
    Gilbert, Stephen E.
    Tew, Garry A.
    Bourke, Liam
    Winter, Edward M.
    Rosario, Derek J.
    EXPERIMENTAL PHYSIOLOGY, 2013, 98 (09) : 1401 - 1410
  • [29] Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
    Koivisto, P
    Kononen, J
    Palmberg, C
    Tammela, T
    Hyytinen, E
    Isola, J
    Trapman, J
    Cleutjens, K
    Noordzij, A
    Visakorpi, T
    Kallioniemi, OP
    CANCER RESEARCH, 1997, 57 (02) : 314 - 319